Host cell protein

About
Privacy
Disclaimer

Graph Chatbot

Related publications (30)

Page 2 of 2

Efficient and reproducible mammalian cell bioprocesses without probes and controllers?

Florian Maria Wurm, Mohamed Farhat, David Hacker, Lucia Baldi Unser, Matthieu Dreyer, Martino Reclari

Bioprocesses for recombinant protein production with mammalian cells are typically controlled for several physicochemical parameters including the pH and dissolved oxygen concentration (DO) of the culture medium. Here we studied whether these controls are ...

Elsevier2011

OrbShake Bioreactors for Mammalian Cell Cultures : Engineering and Scale-up

Most of the biopharmaceuticals nowadays are produced by animal cells. The worldwide demand for a specific group of biopharmaceuticals, the monoclonal antibodies (mAbs), has significantly increased this last decade. The mAbs are used as therapeutics in part ...

EPFL2011

The PiggyBac transposon enhances the frequency of CHO stable cell line generation and yields recombinant lines with superior productivity and stability

Florian Maria Wurm, David Hacker, Lucia Baldi Unser

Generating stable, high-producing mammalian cell lines is a major bottleneck in the manufacture of recombinant therapeutic proteins. Conventional gene transfer methods for cell line generation rely on random plasmid integration, resulting in unpredictable ...

Wiley-Blackwell2011

Transient Gene Expression in HEK-293E Cells for Recombinant Protein Production : Process Characterization towards GMP Approval

The growing demand of biopharmaceutical products is boosting the market for therapeutic recombinant proteins (r-proteins). More than half of the 140 r-proteins that have gained approval for human therapeutic use are manufactured in mammalian cells that mak ...

EPFL2010

Lentiviral Vector-Mediated Gene Delivery for the Generation of Chinese Hamster Ovary Cell Lines with Improved Productivity and Stability

Recombinant cell line generation by standard transfection techniques is a time-consuming and labor-intensive process often leading to an unpredictable outcome as transgene integration is a rare, random event. Consequently, the population of cells obtained ...

EPFL2010

Transient recombinant protein expression in mammalian cells : the role of mRNA level and stability

Sarah Wulhfard

Transient gene expression (TGE) is a rapid method for generating recombinant proteins in mammalian cells, but the volumetric productivities for secreted proteins in transiently transfected CHO DG44 cells are typically more than an order of magnitude lower ...

EPFL2009

Use of Orbital Shaken Disposable Bioreactors for Mammalian Cell Cultures from the Milliliter-Scale to the 1,000-Liter Scale

Alfio Quarteroni, Florian Maria Wurm, David Hacker, Mathieu Benjamin Stettler

Driven by the commercial success of recombinant biopharmaceuticals, there is an increasing demand for novel mammalian cell culture bioreactor systems for the rapid production of biologicals that require mammalian protein processing. Recently, orbitally sha ...

2009

Orbitally shaken bioreactors for mammalian cell culture : engineering characterization and bioprocess scale-up

Driven by the commercial success of recombinant biopharmaceuticals, there is an increasing demand for novel, cost-effective mammalian cell culture bioreactor systems for the production of biologicals requiring mammalian protein processing. Recently, orbita ...

EPFL2009

Development of high-titer transient gene expression processes for manufacturing recombinant proteins

Gaurav Backliwal

The market for recombinant therapeutic proteins (including antibodies) is estimated to be greater than $50-billion and has a compounded annual growth rate of around 20%. More than 50% of all approved processes for manufacturing recombinant proteins use mam ...

EPFL2008

Recombinant protein production by large-scale transient gene expression in mammalian cells : state of the art and future perspectives

Florian Maria Wurm, David Hacker, Lucia Baldi Unser

The expansion of the biologics pipeline depends on the identification of candidate proteins for clinical trials. Speed is one of the critical issues, and the rapid production of high quality, research-grade material for preclinical studies by transient gen ...

Kluwer Academic Publishers, Springer2007